Alpha-lipoic acid changed selected vascular markers after stroke
A placebo-controlled trial reported improvements in vascular measurements and hs-CRP, alongside nonsignificant results for other inflammation markers.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Based on the abstract, alpha-lipoic acid improved selected vascular measurements and an inflammation marker compared with placebo in people who had recently experienced a stroke. Other inflammatory markers showed no statistically significant differences. These are marker outcomes, so the results do not establish that supplementation prevents another stroke or other cardiovascular events.
Only marker outcomes are reported. The abstract omits effect sizes, confidence intervals and adverse-event results, limiting assessment of the magnitude and safety of any changes.
What researchers found
Flow-mediated dilation
Alpha-lipoic acid versus placebo after 12 weeks; described as an improvement, without a reported effect size or confidence interval.
What changed
Researchers measured carotid artery wall thickness, flow-mediated dilation and blood markers of inflammation. The abstract calls the vascular and hs-CRP changes improvements, but does not give their size or uncertainty intervals.
The nonsignificant results
TNF-α and IL-6 showed no statistically significant changes between groups or within either group. That does not prove an absence of biological effects; the abstract provides no estimates to judge their possible size.
The original publication
The effect of alpha-lipoic acid supplementation on vascular function and inflammation in patients newly experienced stroke.
Mohammadi V, Aghababaee SK, Khorvash F et al.
J Res Med Sci · 2025
- PubMed ID
- 41623448
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.